A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 260
Summary
- Conditions
- Dyslipidemias
- Hyperlipidemias
- Hyperlipoproteinemias
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 40 years and 125 years
- Gender
- Both males and females
Description
This study is intended to enable selection of a dose(s) for future development of vupanorsen for cardiovascular (CV) risk reduction and hypertriglyceridemia.
This study is intended to enable selection of a dose(s) for future development of vupanorsen for cardiovascular (CV) risk reduction and hypertriglyceridemia.
Tracking Information
- NCT #
- NCT04516291
- Collaborators
- TIMI Study Group
- Investigators
- Study Director: Pfizer CT.gov Call Center Pfizer
Get Well Soon